Navigation Links
EntreMed Reports First Quarter 2009 Financial Results
Date:5/6/2009

ROCKVILLE, Md., May 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported financial results for the three months ended March 31, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

The Company reported a net loss for the first quarter of approximately ($3.5 million), or ($0.04) per share, compared with a net loss of ($8.3 million), or ($0.10) per share, for the same period last year. The Company did not report any revenues for the first quarter 2009. As of March 31, 2009, the Company had cash and short-term investments of approximately $20.8 million.

Kathy R. Wehmeir-Davis, Principal Accounting Officer, commented on the first quarter results, "The Company's first quarter 2009 financial results were in line with our projections. During the first quarter, the Company realized significant cost savings as a result of our strategy to accelerate the clinical development of our priority Aurora A and angiogenic kinase inhibitor, ENMD-2076, and to focus our financial resources primarily on activities that support the advancement of this program. We expect operational expenses to remain at similar levels through the second quarter. Consistent with the past few years, we anticipate recording royalty revenue from Celgene's sales of Thalomid(R) beginning in the third quarter."

Michael M. Tarnow, Executive Chairman commented, "Our first quarter operating results are a testimony to our diligence in streamlining operations and reducing non-essential expenditures. The corporate restructuring effort is substantially complete and the team is focused primarily on the clinical development of ENMD-2076. The Board remains enthusiastic about this exciting compound and believes the recent realignment and continued commitment of the EntreMed team position the Company to pursue and advance prospective partnerships for the ENMD-2076 clinical program."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company focusing primarily on the development of its priority program, ENMD-2076, for the treatment of cancer. ENMD-2076 is an Aurora A and angiogenic kinase inhibitor, which is currently in Phase 1 studies in patients with solid tumors and multiple myeloma. In addition, multiple Phase 1 and 2 clinical trials are ongoing for MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, and ENMD-1198, a novel tubulin-binding agent. The Company also has an approved IND application for Panzem(R) in the treatment of rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

                                       ENTREMED, INC.
                               SUMMARY OF OPERATING RESULTS

                                    Three Months Ended
                                        March 31,
                                                     2009              2008

    Total revenues                           $           0      $           0

    Research and development                 $   1,953,460      $   6,187,203

    General and administrative               $   1,159,721      $   1,982,994

    Net Loss                                 $  (3,516,755)     $  (8,346,456)

    Net loss per share attributable to
    common shareholders (basic and diluted)  $       (0.04)     $       (0.10)

    Weighted average number of
    shares outstanding (basic and diluted)       87,728,644        84,898,912

    Cash and Short-term Investments            $ 20,826,910      $ 43,643,620

    CONTACT:
    Ginny Dunn
    EntreMed, Inc.
    Associate Director
    Corporate Communications &
    Investor Relations
    (240) 864-2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. EntreMed Reports Fourth Quarter and Year-End 2008 Financial Results
2. EntreMed Focuses on Development of ENMD-2076
3. EntreMed Reports Clinical Program Progress and Company Update
4. EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
5. EntreMed Teams with JSB-Partners to Expedite Partnering of its Aurora Kinase Program
6. EntreMed to Present at the BIO 2008 Annual International Convention
7. EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
8. EntreMed Reports First Quarter 2008 Financial Results
9. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
10. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
11. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... “Nana Nana Boo Boo”: ... of being kind to others. “Nana Nana Boo Boo” is the creation of published ... , Published by Christian Faith Publishing, Michael Rush’s new book presents the importance ...
(Date:7/24/2017)... ... July 24, 2017 , ... “Journey to the Light: The Quest for Happiness ... young woman’s path to finding herself. “Journey to the Light: The Quest for ... Grayson, an experienced writer of newsletters, manuals, and articles, who has recently decided to ...
(Date:7/23/2017)... ... July 24, 2017 , ... Three experts will be ... 59th Annual Meeting & Exhibition, to be held in Denver, CO on July ... and journalists can visit the AAPM Facebook page to watch three speakers present ...
(Date:7/23/2017)... ... July 23, 2017 , ... A 20-year-long study ... Louis, and led by the Minneapolis Veterans Administration Health Care System overwhelmingly supports growing ... disease offers very few benefits. , In the cases involved with this study, ...
(Date:7/23/2017)... ... July 23, 2017 , ... Better education to coaches and ... their work today at the American Orthopaedic Society for Sports Medicine’ ... one to prospectively document the association between sports specialization and lower extremity injuries ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... International plc (NASDAQ: ENDP ) today announced ... network, the Company will be ceasing operations and closing ... Alabama . The closure of the facilities is ... 18 months. The Huntsville location ... and these restructuring actions are intended to better match ...
(Date:7/20/2017)... July 20, 2017  Prime Therapeutics LLC (Prime) released this ... M.D., following today,s Institute for Clinical and Economic Review,s (ICER) ... the effectiveness and value of abuse-deterrent formulations (ADF) of opioids. ... roundtable at the meeting. ... cost benefit to the use of abuse-deterrent formulations (ADF) in ...
(Date:7/17/2017)... , July 17, 2017  MedX Holdings, Inc., the ... testing, strengthening and rehabilitation equipment, today announced the national ... MedX is considered the gold standard for the treatment ... specialized medical strengthening equipment. ... with the physician or practice who prescribe the MedX ...
Breaking Medicine Technology: